Literature DB >> 20656954

Outcome following saphenopopliteal surgery: a prospective observational study.

A Ikponmwosa1, N Bhasin, M J Weston, D C Berridge, D J A Scott.   

Abstract

OBJECTIVES: High recurrence rates following small saphenous varicose vein surgery have been reported. The aim of this study was to ascertain initial success rates following saphenopopliteal junction (SPJ) surgery using pre- and postoperative duplex scanning.
METHODS: A prospective study was performed on patients with ultrasound-proven SPJ reflux. Patients underwent preoperative duplex skin marking and a postoperative quality assurance scan.
RESULTS: Ninety procedures were performed in 88 patients. The SPJ was successfully ligated in 87 (96.7%) cases. Reflux was completely abolished in 51 (56.7%) cases, but persisted solely in the small saphenous vein (SSV) in 32.2%. Subsequently, 10 consecutive patients underwent 11 SPJ ligations with stripping of the SSV. Follow-up ultrasound scan demonstrated successful ligation of the SPJ and elimination of superficial venous reflux.
CONCLUSION: This study demonstrates that preoperative duplex SPJ marking results in a high percentage of successful ligation. Given that residual persistent reflux was avoided in patients who underwent stripping of the SSV, we propose that patients who require SPJ surgery undergo duplex marking along with specific consideration with regard to treatment of the residual SSV.

Entities:  

Mesh:

Year:  2010        PMID: 20656954     DOI: 10.1258/phleb.2009.009001

Source DB:  PubMed          Journal:  Phlebology        ISSN: 0268-3555            Impact factor:   1.740


  1 in total

1.  Mechanochemical endovenous ablation versus radiofrequency ablation in the treatment of primary small saphenous vein insufficiency (MESSI trial): study protocol for a randomized controlled trial.

Authors:  Doeke Boersma; Ramon R J P van Eekeren; Hans J C Kelder; Debora A B Werson; Suzanne Holewijn; Michiel A Schreve; Michel M P J Reijnen; Jean Paul P M de Vries
Journal:  Trials       Date:  2014-10-29       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.